Prophase Labs Stock Today
| PRPH Stock | USD 0.45 0.01 2.17% |
Performance0 of 100
| Odds Of DistressLess than 45
|
ProPhase Labs is trading at 0.45 as of the 30th of January 2025. This is a 2.17 percent decrease since the beginning of the trading day. The stock's open price was 0.46. ProPhase Labs has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. The company has 23.87 M outstanding shares of which 116.38 K shares are at this time shorted by private and institutional investors with about 7.04 trading days to cover. More on ProPhase Labs
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
ProPhase Stock Highlights
| Chairman and CEO | Ted Karkus |
| Thematic Ideas | (View all Themes) |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Management, Management, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
| Financial Strength | |
ProPhase Labs (PRPH) is traded on NASDAQ Exchange in USA. It is located in 711 Stewart Avenue, Garden City, NY, United States, 11530 and employs 113 people. ProPhase Labs is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.98 M. ProPhase Labs conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 23.87 M outstanding shares of which 116.38 K shares are at this time shorted by private and institutional investors with about 7.04 trading days to cover.
ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ProPhase Labs Probability Of Bankruptcy
Ownership AllocationProPhase Labs owns a total of 23.87 Million outstanding shares. ProPhase Labs holds 14.33 pct. of its outstanding shares held by insiders and 7.63 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ProPhase Ownership Details
ProPhase Labs Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. ProPhase Labs market risk premium is the additional return an investor will receive from holding ProPhase Labs long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.20) | |||
| Jensen Alpha | (2.04) | |||
| Total Risk Alpha | (3.02) | |||
| Treynor Ratio | 0.9242 |
ProPhase Stock Against Markets
ProPhase Labs Corporate Management
| Billy White | Consultant | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Kamal Obbad | Senior Genomics | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.